Southeast Asia’s femtech ecosystem has expanded significantly in recent years, growing beyond period tracking and wellness content into areas including fertility, diagnostics, maternal health, menopause and sexual health. A December 2025 report by the United Nations Economic and Social Commission for Asia and the Pacific described Southeast Asia as the world’s fastest-growing femtech market, supported by rising adoption, women-led businesses and an expanding innovation ecosystem.
The question now is not whether the sector can attract attention, but whether its companies can build clinically credible and commercially sustainable models at regional scale. The six startups below represent different answers to that scaling question, from digital clinics to wearable medical devices to fertility marketplaces.
Here’s how Southeast Asia’s top 5 promising startups are moving beyond hype
Ease Healthcare: building the region’s largest women’s health ecosystem
Ease Healthcare was founded in 2020 with a clear goal: women’s healthcare in Southeast Asia was neither convenient nor discreet, and that gap was costing women access to basic services like contraception, STI testing and sexual health consultations. The Singapore-based company built a platform combining telehealth, community, health tracking and education into a single app, and has since expanded services to the Philippines.
Ease raised a US$1.3 million seed round in 2021, led by Insignia Ventures Partners, which the company describes as the largest seed round for any femtech startup in Southeast Asia at the time. Since then, the company has grown its community to over 100,000 women across Southeast Asia and expanded its offering in 2024 with Elevate, a metabolic health and weight management platform. The willingness to diversify beyond core reproductive health into adjacent categories like metabolic health suggests a company thinking about lifetime customer relationships rather than a single product use case, which is precisely the kind of expansion path femtech companies need if they want durable revenue.
EloCare: putting menopause data on a wearable device
Menopause remains one of the least discussed and least funded categories in women’s health globally, despite affecting every woman who lives long enough to experience it. EloCare, a Singapore-based startup founded by biomedical engineering researcher Dr Mabel Yen Ngoc Nguyen, set out to change that by building the internet of medical things infrastructure for menopause specifically.
The company developed a wearable device paired with an app that monitors more than 35 symptoms of menopause, recording and interpreting data to give women clearer insight into their condition in partnership with their doctors. EloCare won Enterprise Singapore’s Healthcare Open Innovation Challenge, giving the company an opportunity to develop and deploy its research-backed solution with healthcare partners. That kind of institutional grant funding, rather than pure venture capital, has historically been an important funding channel for menopause-focused femtech, a category investors have been slower to back at scale relative to fertility or general wellness.
Ovy Health: bridging fertility treatment and everyday wellness
Fertility technology in Southeast Asia has traditionally meant either consumer cycle-tracking apps or high-cost clinical IVF pathways, with relatively little in between. Ovy Health has positioned itself in that middle ground, offering personalised care plans, AI-based tracking tools and access to fertility specialists to help individuals navigate reproductive health decisions with more structure than a tracking app alone provides.
Ovy Health was founded in Singapore and operates through a regional network of fertility specialists and clinic partners across Southeast Asia. Its offering combines fertility assessments, personalised care plans, specialist access and lifestyle support, positioning it between a consumer tracking app and a conventional fertility clinic. By integrating medical coordination with nutrition, hormonal health and emotional wellbeing, the company reflects a wider shift towards treating fertility as part of a broader continuum of reproductive health.
Kindred: building a hybrid women’s healthcare model in the Philippines
Access to specialist women’s healthcare in the Philippines has historically meant long wait times, limited OB-GYN availability outside major cities and healthcare services that were not designed with continuity of care in mind. Kindred, founded in 2021 by nurse Jessica de Mesa-Lim and medtech entrepreneur Abetina Valenzuela, built a hybrid model combining a physical clinic with telehealth to address that gap directly.
The company has grown steadily and credibly. It raised US$1 million in seed funding in 2023 to open its first physical clinic in Bonifacio Global City, followed by a pre-Series A round in 2024 comprising US$2.5 million in initial funding and a further US$3 million committed upon the completion of agreed milestones, led by Integra Partners. By 2024, Kindred had served more than 20,000 women and partnered with over 70 doctors across 25 subcategories of care, and the company is now expanding hybrid clinics into rural provinces outside Metro Manila, aiming to hyperlocalise care for women in underserved areas. Kindred is one of the Philippines’ most visibly funded femtech companies, which is a useful signal for what institutional investors are willing to back in that market specifically.
Lumirous: building Malaysia’s fertility and reproductive health marketplace
Founded in 2020 by Anna Yamauchi, Lumirous set out to solve a specific problem: women and couples facing fertility challenges in Malaysia often did not know where to find trustworthy information, products or specialist referrals in one place. The company built a one-stop platform combining fertility education, a curated marketplace of conception products and partnerships with clinics across the country.
Lumirous has collaborated with more than 15 fertility clinics across Malaysia and positions itself for the broader Southeast Asian market, including Singapore and Indonesia. Within Malaysia’s femtech landscape specifically, menstrual care remains the dominant category by number of businesses, but Lumirous is one of the relatively few Malaysian femtech companies with publicly disclosed institutional funding, giving it a distinctive position within Malaysia’s reproductive and fertility health market.
Biorithm: monitoring pregnancy complications before they become emergencies
More than 700 women die each day from preventable causes related to pregnancy and childbirth, according to World Health Organisation figures. This statistic reflects how maternal mortality is shaped not only by medical knowledge, but also by women’s access to consistent, timely care during pregnancy. Biorithm, a Singapore-based medtech company spun off from Nanyang Technological University, was established to help close this monitoring gap.
The company’s flagship product, Femom, is a medical-grade wearable that tracks foetal heart rate, maternal heart rate and uterine contractions, transmitting the data to clinicians through a connected app and enabling monitoring between scheduled clinic visits, with the potential to identify warning signs earlier.
Biorithm raised US$3.5 million in Series A funding in 2023, co-led by Adaptive Capital Partners and SEEDS Capital, Enterprise Singapore’s investment arm, with the funding supporting both regional expansion and clinical studies to support an FDA premarket submission in the United States. Of the six companies here, Biorithm’s device-based clinical approach places it closest to a genuine medtech classification rather than a pure digital health product, which brings both a higher regulatory bar and a stronger long-term defensibility once that bar is cleared.
Building credibility takes longer than building an app
What separates the companies likely to scale from those that will remain locally relevant is not really about which health category they address. It is about whether they can build the clinical credibility, institutional partnerships and reimbursement or insurance pathways that turn a useful app into a trusted healthcare provider. Companies like Kindred and Biorithm, which have invested in physical infrastructure or regulatory pathways alongside their digital products, are building a different kind of moat than a pure consumer app can achieve on its own.
The next phase of Southeast Asia’s femtech sector is likely to be shaped less by how many startups launch and more by which of them can convert institutional grants, government co-funding and early venture rounds into the kind of clinical trust that gets a product into insurance panels, hospital referral networks and employer health benefits. That is a slower and less headline-friendly path than a consumer app hitting a download milestone, but it is the one that determines which of these companies are still operating and mattering, five years from now.